SCA
IONS icon

Stonebridge Capital Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Stonebridge Capital Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-69
Closed -$2.83K – 959
2023
Q2 		$2.83K Buy
+69
New +$2.65K ﹤0.01% 778
2021
Q4 		– Sell
-29
Closed -$1K – 1001
2021
Q3 		$1K Hold
29
– – ﹤0.01% 894
2021
Q2 		$1K Buy
+29
New +$1.14K ﹤0.01% 988

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Stonebridge Capital Advisors's IONS Position: Q3 2023 in Review

Stonebridge Capital Advisors sold out of Ionis Pharmaceuticals (IONS) in Q3 2023, closing a stake of 69 shares — an estimated $2.83K sold.

Stonebridge Capital Advisors first reported a position in IONS in Q2 2021 and held it in 3 quarters. The position peaked at $2.83K in Q2 2023. 310 funds tracked by Wall St. Rank hold IONS as of Q3 2023.

  • Stonebridge Capital Advisors reported no remaining Ionis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 69 Ionis Pharmaceuticals shares in Q3 2023, an estimated $2.83K.
  • Stonebridge Capital Advisors first reported a position in Ionis Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Stonebridge Capital Advisors's Ionis Pharmaceuticals position peaked at $2.83K in Q2 2023.
  • 310 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.